CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq:DYAX) announced that two oral abstracts were presented yesterday highlighting collective results from the Company’s Phase II trials of DX-88 (ecallantide), including its most recent results from its EDEMA2 trial, for the treatment of acute attacks in hereditary angioedema (HAE). The abstracts were presented at the American College of Allergy, Asthma & Immunology 2007 Annual Meeting being held in Philadelphia, PA from November 9 through November 15, 2006. The presentations were made on November 13 by the following DX-88 investigators: Dr. William Lumry, M.D., AARA Research Center, Dallas, TX, and Dr. H. Henry Li, M.D., Ph.D., FACAAI, Institute for Asthma and Allergy, Wheaton, MD. The presentations featured overall positive results from three completed Phase II trials highlighting final results from the Phase II, EDEMA2 trial. DX-88 is being developed in a joint venture with Genzyme Corporation for the treatment of HAE, a debilitating and potentially life-threatening inflammatory condition characterized by unpredictable attacks of severe peripheral, abdominal and/or laryngeal pain and swelling.
